Unlike existing GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) or dual agonists like tirzepatide (Mounjaro, Zepbound), Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously
PMID 37364590
Epigenetic regulation of diverse regulated cell death modalities in cardiovascular disease: insights into necroptosis, pyroptosis, ferroptosis, and cuproptosis
About the Author: Anthony Walker, PhD, Managing Partner, Alacrita Consulting Anthony leverages more than 35 years of experience, including over a decade spent building & managing a biotechnology company and over 20 years as a management consultant to the pharmaceutical & biotech industries
Copper peptides are not a magic bullet no single ingredient is
Clinicians are Read More